ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Even though the current first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) are being used for treating patients with CML with great success [5, 6], still some patients (~10%-15%) fail to TKI treatment, due to mutations within the kinase domain of BCR-ABL1 protein [3, 7].